TipRanks on MSN
MiNK Therapeutics Appoints Dr. John Holcomb as Director
The latest update is out from MiNK Therapeutics ( (INKT) ).
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical ...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured from U.S ...
The authors found comparable results among patients in all 3 donor categories. For instance, the 2-year overall survival (OS) ...
On September 26, 2025, Mesoblast Limited announced that its allogeneic cell therapy products, including Ryoncil®, are designated as U.S. origin products and are not subject to tariffs on imported ...
This article explores how stem cell therapies and organoid models are advancing Alzheimer’s research. It highlights progress ...
MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T ...
When Sherry received a diagnosis of endometrial cancer, her life was forever changed. Learn more about her journey.
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream ...
UCLA researchers have made strides in developing a stem cell gene therapy for alpha thalassemia major, a severe, inherited ...
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback